A New York City start-up backed by big investors and led by an experienced management team is looking to break into the obesity and metabolic disease space. The company, called Metsera, Inc., was publicly unveiled on 18 April but has been in operation for more than two years and already has assets in early clinical development.
Key Takeaways
- Metsera is a start up working in obesity and metabolic disease, with an eye on developing combination drugs.
- The company’s CEO Clive Meanwell is well known in the industry and previously led The Medicines Company, which was sold to Novartis
CEO Clive Meanwell, former CEO of The Medicines Company, built that company from the ground up and established it as a hospital specialist before eventually homing in on the PCSK9 inhibitor inclisiran – the drug that eventually became Leqvio – and positioning the company for a sale. (Also see "It Has Been A Long Farewell To The Medicines Company" - Scrip, 26 November, 2019
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
